Regentis Biomaterials Ltd.

Tissue engineering company focused on commercialising its Gelrin™ platform technology for bone, spine and cartilage repair.

The start-up company was founded in 2004 and is seed funded by the Technological Incubator (Technion Research and Development Foundation Ltd.), ProSeed Venture Capital Fund, Shalom Equity fund and Vitalife.

Yehiel Tal, CEO
Dror Seliktar, Dr., CSO
Eli Peled, MD, Manager of Clinical Affairs

Jeff Dykan
Zohar Gendler
Benjamin Soffer
Yehiel Tal
Dror Seliktar, Dr.

Building 30, MATAM, Advanced Technologies Center
P.O.Box 15054
Haifa 31905
Israel
Phone: +972-4-8546617
Fax: +972-4-8546644

The company has developed a state-of-the-art tissue regeneration substrate called Gelrin. This technology is based on a biosynthetic hybrid hydrogel comprised of a biological backbone and synthetic cross-links. The biological domains excert excellent healing properties; the material’s synthetic cross-links provide the material with superior physical characteristics. The biodegradation of the material is fully controllable. The company hopes to have its first orthopaedic product ready within the next three years: GelrinCartilage, which is a chondrogenically enriched ingrowth matrix for cartilage regeneration. Two additional products are in the pipeline for regeneration of bone and spine.

For comprehensive patent information please refer to the espacenet databases.